DRDianxu Ren

Dianxu Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dianxu Ren has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring the Optimal Clinical Cutoff for the IGT‐AD Distress Subscale Adapted for AD Biomarker Results Disclosure

    by Dianxu Ren, Jeong Eun Kim, Joshua D Grill, Jennifer H Lingler

    Background: The Impact of Genetic Susceptibility Testing for Alzheimer's Disease (IGT‐AD) instrument, developed to assess the psychological effects of learning genetic information specific to Alzheimer's disease (AD), has been widely used in the literature. Identifying a cutoff score for this screening instrument is crucial for rapidly and efficiently identifying individuals in need of psychological intervention, including those learning the results of non‐genetic AD biomarker testing. This study aims to explore the optimal cutoff score and evaluate the predictive powers of an adapted IGT‐AD Distress subscale for identifying distress in cognitively symptomatic older adults learning the results of amyloid PET testing. Method: We adapted the IGT‐AD instrument by replacing reference to genetic testing with reference to biomarker testing. A total of 96 cognitively symptomatic research participants were assessed for psychological impact using this adapted instrument and the Impact of Event Scale (IES) as a gold standard comparison diagnostic tool. The optimal cutoff point for the modified IGT‐AD in detecting distress was determined by evaluating the sensitivity and specificity of various cutoff scores, with an IES cutoff of 26 used as the gold standard. Receiver Operating Characteristic (ROC) analysis was performed, and the area under the curve (AUC) was calculated to evaluate the predictive accuracy of the IGT‐AD. The Youden index was used to identify the cutoff point that maximized sensitivity and specificity. Result: The mean age of participants was 72.4 years, 40.6% were male, 71.6% were White race, 21% were Black race, and 20% were Hispanic ethnicity. Most (55.2%) held bachelor's or post‐bachelor's degrees and 71.9% were married or cohabiting. The optimal cutoff point for the modified IGT‐AD Distress subscale was determined to be 22, with a sensitivity of 77.1% and specificity of 82.0%. The AUC for distress was 0.86 (95% CI: 0.78–0.94), indicating excellent predictive power. Conclusion: The findings suggest that an adapted IGT‐AD Distress subscale score above the identified cutoff of 22 is effective in detecting psychological distress in cognitively symptomatic persons learning their AD biomarker status. This cutoff may have practical applications in clinical and research settings for screening and early intervention.

  • Open Access

    Estimating the optimal cutoff for the IGT‐AD Distress subscale adapted for amyloid PET results disclosure

    by Dianxu Ren, Kim Jeong Eun, Joshua D. Grill, Jennifer H. Lingler

    INTRODUCTION: Research on diagnostic and biomarker disclosure has significantly increased, particularly in the field of Alzheimer's disease (AD). The psychological impact of learning amyloid positron emission tomography (PET) results has been frequently assessed using the Impact of Genetic Testing for Alzheimer's Disease (IGT‐AD) instrument. Establishing an optimal cutoff score for this screening tool is essential for efficiently identifying individuals who may require psychological support after amyloid PET disclosure. In this study, we aimed to determine the optimal distress cutoff for the adapted IGT‐AD instrument after amyloid PET result disclosure in cognitively symptomatic older adults. METHODS: We adapted the IGT‐AD instrument by replacing reference to genetic testing with reference to amyloid PET testing. A total of 98 participants with either mild cognitive impairment (MCI) or dementia were assessed for psychological impact using this adapted instrument and the Impact of Event Scale (IES; cutoff = 26) as a gold standard. Receiver operating characteristic analysis determined the optimal distress cutoff, with the Youden index maximizing sensitivity and specificity. The area under the curve (AUC) was calculated to evaluate the predictive accuracy of the IGT‐AD. RESULTS: The mean age of participants was 72.6 years, 41.8% were male, 77.6% were White, 16.3% were Black, and 15.3% were of Hispanic ethnicity. Most (57.2%) held bachelor or post‐bachelor degrees, and 73.5% were married or cohabiting. The optimal cutoff point for the modified IGT‐AD Distress subscale was determined to be 15, with a sensitivity of 100% and specificity of 70.1%. The AUC for distress was 0.89 (95% confidence interval: 0.82–0.95), indicating good predictive power. DISCUSSION: A distress score ≥ 15 on the adapted IGT‐AD appears to be a suitable cutoff for detecting significant psychological distress in cognitively symptomatic individuals learning their amyloid PET result. This cutoff has potential clinical and research applications for screening and early intervention. Highlights: The Impact of Genetic Testing for Alzheimer's Disease (IGT‐AD) instrument is widely used to assess the psychological impact of Alzheimer's disease biomarker disclosure. Establishing a cutoff score is essential for identifying individuals needing psychological support. Receiver operating characteristic analysis determined the optimal IGT‐AD distress cutoff, using Impact of Event Scale (cutoff = 26) as the gold standard. The optimal cutoff for moderate to severe distress on the adapted IGT‐AD is 15. Larger studies are needed to validate this cutoff.


  • Open Access

    Exploring the Impact of Self‐Efficacy on Depression and Anxiety Symptoms in Mild Cognitive Impairment Patients and Their Care Partners: A Dyadic Analysis

    by Dianxu Ren, Lisa K Tamres, Jennifer H Lingler

    Background: Research on the relationship between self‐efficacy and symptoms of depression and anxiety among individuals with mild cognitive impairment (MCI) has been limited. Furthermore, few studies have explored this relationship within the context of dyadic couples (patient/care partners) rather than focusing solely on individuals. The purpose of this study was to examine the associations between self‐efficacy in patient/care partner couples dealing with mild cognitive impairment and their symptoms of depression and anxiety using a dyadic analysis approach.Method: We utilized baseline data from a NIH‐funded study for this cross‐sectional analysis. Participants were interviewed regarding self‐efficacy using The Coping Self‐Efficacy Scale, depressive symptoms using the Center for Epidemiological Studies Depression scale, and state anxiety using the Spielberger State‐Trait Anxiety Inventory. We employed the Actor‐Partner Interdependence Model (APIM) to examine the relationships between outcomes (depressive symptoms and state anxiety) and the predictor (self‐efficacy scale) for patients with MCI and their care partners controlling for dyads' age, gender, education level and self‐efficacy respectively.Result: The sample consisted of 82 dyads comprising patients with MCI (59.8% male, average age 72.6 years, average education 16.5 years) and their care partners (24.4% male, average age 66.8 years, average education 15.5 years). The average self‐efficacy, depression and anxiety were 203.6±28.7, 6.51±4.29 and 26.0±6.01 for patient and 202.4±36.9, 7.61±7.66 and 26.8±7.40 for care partner respectively. Regarding depression, there was a significant actor effect of self‐efficacy for both patients and care partners. Increased self‐efficacy was associated with decreased depression for both patients (β = ‐0.07, P<0.001) and care partners (β = ‐0.11, P<0.001). A marginally significant partner effect of care partner’s self‐efficacy on patient depression was observed (β = ‐0.05, P = 0.066), but no effect of patient’s self‐efficacy on caregiver’s depression was found. For anxiety, there was a significant actor effect of self‐efficacy for both patients and care partners. Increased self‐efficacy was associated with decreased anxiety for both patients (β = ‐0.11, P<0.001) and care partners (β = ‐0.11, P<0.001). However, no partner effects were observed.Conclusion: Our findings emphasize the importance of considering patient/care partner dyads to better understand the complex interplay between psychological outcomes and predictors in the context of mild cognitive impairment.


  • Open Access

    Neonatal Diet Type and Associations With Adverse Feeding Outcomes in Neonates With Critical Congenital Heart Defects

    by Jessica A. PhD Davis, Kelley Baumgartel, Tracy Ba Baust, Yvette P. Conley, Michael J. Morowitz, Dianxu Ren, Jill R. PhD Demirci

    Background: Neonates with critical congenital heart defects (CCHD neonates) experience high rates of feeding intolerance, necrotizing enterocolitis (NEC), and malnutrition. The benefits of human milk and direct chest/breastfeeding are well known, but research is limited in CCHD neonates. Therefore, the purpose of this study is to examine the impact of neonatal diet and feeding modality on the incidence of feeding intolerance, NEC, and malnutrition among a cohort of CCHD neonates. Methods: A single-center retrospective study was conducted using electronic health record data of CCHD neonates admitted to a cardiac intensive care unit between April 2016 and April 2020. Regression models were fit to analyze associations between neonatal diet, feed modality, and adverse feeding outcomes. Results: Seventy-four CCHD neonates were included. Increased days of direct chest/breastfeeding were associated with fewer signs of gastrointestinal distress (P = .047) and bloody stools (P = .021). Enteral feeding days of “all human milk” were associated with higher growth trajectory (P < .001). Conclusions: Human milk and direct chest/breastfeeding may be protective against some adverse feeding outcomes for CCHD neonates. Larger, multicenter cohort studies are needed to continue investigating the effects of neonatal diet type and feeding modality on the development of adverse feeding outcomes in this unique population.


  • A Clinical Nurse Specialist–Led Quality Improvement Initiative to Identify Barriers to Adherence to a Bundle for Central Line Maintenance

    by Melissa Dawn Dnp Harlan, Jamilyn Sue Msn Kennell, Wendy Msn Lucas, Dianxu Ren, Patricia K. PhD Tuite

    Purpose: This clinical nurse specialist–led quality improvement project identified barriers to adherence to a bundle for central line maintenance and examined the relationship between increased bundle adherence and central line–associated bloodstream infections. Project Description: Oncology and critical care nurses were surveyed to identify barriers to adherence to a bundle for central line maintenance. Targeted initiatives based on survey responses were implemented focusing on antimicrobial bathing, increasing confidence in an evidence-based bundle, and its ability to reduce infections. Adherence and central line–associated bloodstream infection rates were monitored at baseline and at 3, 9, and 15 months post intervention. Outcomes: Adherence to bundle elements improved post intervention in 4 areas in critical care units: correctly labeling catheter dressings, maintaining an occlusive dressing, clamping unused catheter lumens, and daily antimicrobial bathing. In oncology units, adherence improved in clamping unused lumens and daily antimicrobial bathing. At 9 months post intervention, infection rates decreased from 6.08 to 1.48 in critical care units and 3.13 to 0.30 in oncology units. Conclusions: Identifying unit-specific barriers to adherence to bundles for central line maintenance and implementing targeted initiatives to reduce barriers increase adherence and prevent central line infections.


  • Associations between late‐life cardiometabolic risk factors and dementia

    by Dianxu Ren, Oscar L Lopez, Jennifer H Lingler, Yvette Conley

    Background: Late‐life cardiometabolic risk factors (overweight/obesity, hypertension, hypercholesterolemia, and diabetes) have been inconsistently reported to associate with dementia, with both increased and decreased risks. The purpose of this study was to examine such associations with incident dementia using the large national dataset from National Alzheimer’s Coordinating Center (NACC).Method: We used NACC dataset from 2005 to December 2020 and restricted our analysis to patients who were 65 years and older at initial visit, had an APOE genotype available, first visit with dementia free and had a minimum of one follow‐up visit. The cardiometabolic risk factors were measured at initial visit. Piecewise multivariable Cox proportional hazard models accounting for non‐proportional hazards were performed to examine the associations of the 4 cardiometabolic risk factors with incident dementia, controlling for age, gender, race, education and APOE genotype. Adjusted hazard ratio (aHR) and 95% confidence interval (CI) were reported.Result: For the defined cohort (N=13,068), mean age at enrollment was 74.9 years, participants were more female (59%), and non‐Hispanic white (76.9%). Over an average of 4.8 years follow‐up, 2817 (21.6%) developed dementia. Both diabetics and hypertension demonstrated the increased risk of dementia compared to non‐diabetics (aHR=1.26, 95% CI (1.12, 1.41), P<0.0001), and to non‐hypertension (aHR=1.09, 95% CI (1.01, 1.19), P=0.026). However, hypercholesterolemia was not associated with dementia (aHR=1.03, 95% CI (0.95, 1.11), P=0.65). Differential BMI effects on incident dementia were observed over the length of follow‐up before dementia diagnosis. During the time of 0‐4 years and 4‐8 years before dementia, increased BMI significantly associated with reduced risk of dementia [aHR=0.96, 95% CI (0.95‐0.97), P<0.001; aHR=0.98, 95% CI (0.96‐0.99), P=0.016], and no effect during the time of 8‐12 years (aHR=0.99, 95% CI (0.96‐1.02), P=0.54). However, for the time longer than 12 years before dementia, higher BMI exhibited a trend of increased risk of dementia (aHR=1.05, 95% CI (0.99‐1.10), P=0.08).Conclusion: Our analyses showed baseline diabetes and hypertension in late‐life are associated with dementia. The BMI‐dementia association likely attribute to a harmful effect of higher BMI with the onset of dementia over a long follow‐up and a potential reverse‐causation effect when the follow‐up is short.

  • Association Between the APOE ɛ2/ɛ4 Genotype and Alzheimer’s Disease and Mild Cognitive Impairment Among African Americans

    by Dianxu Ren, Oscar L. Lopez, Jennifer H. Lingler, Yvette Conley

    We examined the association between APOE ɛ2/ɛ4 with incident Alzheimer’s disease (AD) and mild cognitive impairment (MCI) among African Americans using the national dataset from the National Alzheimer’s Coordinating Center (NACC) from 2005 to September 2019. Compared to ɛ3/ɛ3 carriers, ɛ2/ɛ4 carriers exhibited a similar risk of incident AD (adjusted hazard ratio [aHR] = 0.85, 95% CI [0.39, 1.84]) among the AD cohort and similar risk of incident MCI (aHR = 0.88, 95% CI [0.51, 1.50]) among the MCI cohort. Our findings suggest that, unlike the increased risk of AD and MCI in non-Latino whites, APOE ɛ2/ɛ4 genotype is not associated with the incidence of AD and MCI among African Americans.


  • The effect of APOE ɛ2/ɛ4 genotype on the incidence of Alzheimer's disease (AD) and mild cognitive impairment (MCI) in African Americans

    by Dianxu Ren, Oscar L. Lopez, Jennifer Lingler, Yvette Conley

    Background: The APOE Ɛ2Ɛ4 genotype has been recently reported to associate with increased risk of AD and MCI among non‐Latino whites besides the effects of increased risk of Ɛ4 allele (Ɛ3Ɛ4, Ɛ4Ɛ4). However, there was no study to date on the effects of the Ɛ2Ɛ4 genotype among African American population. The purpose of this study was to examine the associations of APOE Ɛ2Ɛ4 with incident AD dementia and incident of Mild Cognitive Impairment (MCI) among African Americans using the large national dataset from National Alzheimer’s Coordinating Center (NACC).Methods: We used NACC dataset from 2005 to September 2019 and restricted our analysis to subjects who were African Americans, had an APOE genotype available, first visit with dementia free for AD cohort and both dementia and MCI free for MCI cohort, had a minimum of one follow‐up visit. The subjects were classified into 4 groups based on APOE genotyping: Ɛ2Ɛ4, Ɛ2 (Ɛ2Ɛ2, Ɛ2Ɛ3), Ɛ4 (Ɛ4Ɛ4, Ɛ3Ɛ4), with Ɛ3Ɛ3 carriers serving as the reference group. Cox proportional hazard models were performed to examine the associations of APOE Ɛ2Ɛ4 with incident AD and MCI respectively after controlling age, gender, education, baseline cognitive status and year of initial visit. Adjusted hazard ratio (aHR) and 95% confidence interval (CI) were reported.Results: Among AD cohort (N = 2,007), Ɛ2Ɛ4 accounted for 4.9%, Ɛ2/2 and Ɛ2/3 15%, Ɛ3/4 and Ɛ4/4 34.3%, and Ɛ3Ɛ3 45.8%. Over an average of 4.6 years follow‐up, 216 (10.8%) developed AD dementia with the range from 6.3% to 15.7% across 4 groups. Comparing to Ɛ3Ɛ3 carriers, Ɛ2Ɛ4 carriers had a similar risk of incident AD (7.1% vs 8.9%; aHR = 0.85, 95% CI (0.39, 1.84), P = 0.679). Among MCI cohort (N = 1,480), the average follow‐up was 4.5 years and 336 (22.7%) developed MCI with the range from 20.8% to 26.5% across 4 groups. Comparing to Ɛ3Ɛ3 carriers, Ɛ2Ɛ4 carriers had a similar risk of incident MCI (21.1% vs 20.8%; aHR = 0.88, 95% CI (0.51, 1.50), P = 0.637).Conclusions: Unlike the effects on non‐Latino whites, APOE Ɛ2Ɛ4 genotype is not associated with the increased risk of AD and MCI among African Americans.


  • The Effect of the APOE ε2ε4 Genotype on the Development of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) in Non‐Latino Whites

    by Dianxu Ren, Oscar L. Lopez, Jennifer H. Lingler, Yvette Conley

    OBJECTIVES: To examine the associations of APOE ε2ε4 with the development of Alzheimerʼs disease (AD) and mild cognitive impairment (MCI) in non‐Latino whites. DESIGN: Prospective longitudinal cohort study. SETTING: Uniform Data Set from the National Alzheimerʼs Coordinating Center (NACC) between 2005 and August 2018 (data freeze in September 2018). PARTICIPANTS: Participants who were non‐Latino white, had an APOE genotype available, first visit with dementia free for AD cohort and both dementia and MCI free for MCI cohort, and had a minimum of one follow‐up visit (n = 11 871 for AD cohort, and n = 8305 for MCI cohort). MEASUREMENTS: The incidences of AD and MCI were determined based on consensus meetings at each Alzheimerʼs disease center. We used NACC‐derived variables to define individuals experiencing incidents of AD and MCI at the initial visit as well as the follow‐up visits. RESULTS: Among participants in the AD cohort (N = 11 871), ε2ε4 accounted for 2.5%, ε2ε2 accounted for 0.4%, ε2ε3 accounted for 11.0%, ε4ε4 accounted for 4.4%, ε3ε4 accounted for 27.3%, and ε3ε3 accounted for 54.4%. Over an average of 4.6 years follow‐up, 1857 (15.6%) developed AD dementia, with the range from 6.0% to 35.2% across the six groups. Compared to ε3ε3 carriers, ε2ε4 carriers exhibited an increased risk of incident AD (18.4% vs 11.7%; adjusted hazard ratio [aHR] = 1.74; 95% confidence interval [CI] = 1.32‐2.30; P < .0001). Among participants in the MCI cohort (N = 8305), the average follow‐up was 4.7 years, and 1912 (23.0%) developed MCI, with the range from 20.4% to 33.9% across the six groups. Compared to ε3ε3 carriers, ε2ε4 carriers exhibited an increased risk of incident MCI (27.5% vs 21.5%; aHR = 1.52; 95% CI = 1.15‐1.99; P = .003). CONCLUSIONS: The APOE ε2ε4 genotype is associated with the increased risk of AD and MCI in non‐Latino whites. J Am Geriatr Soc 68:1044–1049, 2020